A study was conducted to assess the prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with type 2 diabetes mellitus (T2DM) attending the Dasman Diabetes Institute (DDI) in Kuwait. The study evaluated 267 T2DM patients, with a mean age of 53.2 years and a male predominance (67.4%).
Prevalence of Liver Steatosis and Fibrosis
Liver steatosis (S0-S3) was identified in 72.7% of participants. Forty-eight point eight percent exhibited severe steatosis (S3), twenty-one point six percent moderate steatosis (S2), and eleven point two percent mild steatosis (S1). Minimal or no fibrosis (F0-F1) was present in ninety-two point five percent of the cohort. Moderate fibrosis (F2) was observed in four point one percent, and advanced fibrosis (F3-F4) was identified in three point four percent.
Biomarker Associations
Vibration-controlled transient elastography (VCTE) using controlled attenuation parameter (CAP) scores was utilized to determine liver steatosis and estimate fibrosis severity via liver stiffness measurement (LSM). Significant positive associations were found between CAP scores and BMI (ρ = 0.32, p < 0.001), waist circumference (ρ = 0.200, p = 0.001), triglycerides (ρ = 0.310, p < 0.001), ALT (ρ = 0.325, p < 0.001), AST (ρ = 0.197, p = 0.002), and GGT (ρ = 0.203, p = 0.001). An inverse correlation was observed with HDL-C (ρ = -0.19, p = 0.003). CAP score remained independently associated with BMI, ALT, and LSM in multivariable linear regression analyses. LSM was significantly associated with CAP score, BMI, ALT, AST, and GGT.